Download PDF
Semin Reprod Med 2024; 42(01): 041-048
DOI: 10.1055/s-0044-1787525
Review Article

Anti-Müllerian Hormone: A Molecular Key to Unlocking Polycystic Ovary Syndrome?

David H. Abbott 
1   Department of Obstetrics and Gynecology, University of Wisconsin, Madison, Wisconsin
2   Wisconsin National Primate Research Center, University of Wisconsin, Madison, Wisconsin
3   Endocrinology and Reproductive Physiology Training Program, University of Wisconsin, Madison, Wisconsin
,
Beverly A. Hutcherson
2   Wisconsin National Primate Research Center, University of Wisconsin, Madison, Wisconsin
3   Endocrinology and Reproductive Physiology Training Program, University of Wisconsin, Madison, Wisconsin
4   Dean's Office, University of Wisconsin School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin
,
Daniel A. Dumesic 
5   Department of Obstetrics and Gynecology, University of California, Los Angeles, California
› Author Affiliations Funding This study was funded in part by the National Institutes of Health (NIH) Grants R21 HD102172 (D.H.A.), R01 DK121559 (D.H.A.), P51 OD011106 (D.H.A.), U01 HD044650 (D.A.D., B.H.A., D.H.A.) P50HD071836 (D.A.D.) and Santa Monica Bay Woman's Club (D.A.D.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
› Further Information
    Permissions and Reprints

Abstract

Anti-Müllerian hormone (AMH) is an important component within androgen receptor (AR)-regulated pathways governing the hyperandrogenic origin of polycystic ovary syndrome (PCOS). In women with PCOS, granulosa cell AMH overexpression in developing ovarian follicles contributes to elevated circulating AMH levels beginning at birth and continuing in adolescent daughters of PCOS women. A 6 to 7% incidence among PCOS women of gene variants coding for AMH or its receptor, AMHR2, suggests genetic contributions to AMH-related pathogenesis. Discrete gestational AMH administration to pregnant mice induces hypergonadotropic hyperandrogenic, PCOS-like female offspring with high circulating AMH levels that persist over three generations, suggesting epigenetic contributions to PCOS through developmental programming. Moreover, adult-onset, selective hyperactivation of hypothalamic neurons expressing gonadotropin-releasing hormone (GnRH) induces hypergonadotropic hyperandrogenism and PCOS-like traits in female mice. Both gestational and adult AMH inductions of PCOS-like traits are prevented by GnRH antagonist coadministration, implicating luteinizing hormone–dependent ovarian theca cell testosterone (T) action, mediated through the AR in AMH-induced pathogenesis. Interestingly, gestational or peripubertal exogenous T or dihydrotestosterone induction of PCOS-like traits in female mice, rats, sheep, and monkeys fails to elicit ovarian AMH hypersecretion; thus, AMH excess per se may lead to a distinct pathogenic contribution to hyperandrogenic PCOS origins.

Keywords

neuronal AMH - overexpression of AMH - developmental programming - PCOS etiology - animal models


Publication History

Article published online:
22 June 2024

© 2024. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Cutting A, Chue J, Smith CA. Just how conserved is vertebrate sex determination?. Dev Dyn 2013; 242 (04) 380-387
    CrossrefPubMedGoogle Scholar
  • 2 Cimino I, Casoni F, Liu X. et al. Novel role for anti-Müllerian hormone in the regulation of GnRH neuron excitability and hormone secretion. Nat Commun 2016; 7: 10055
    CrossrefPubMedGoogle Scholar
  • 3 Tumurbaatar T, Kanasaki H, Tumurgan Z, Oride A, Okada H, Kyo S. Effect of anti-Müllerian hormone on the regulation of pituitary gonadotropin subunit expression: roles of kisspeptin and its receptors in gonadotroph LβT2 cells. Endocr J 2021; 68 (09) 1091-1100
    CrossrefPubMedGoogle Scholar
  • 4 Chauvin M, Meinsohn MC, Dasari S. et al. Cancer-associated mesothelial cells are regulated by the anti-Müllerian hormone axis. Cell Rep 2023; 42 (07) 112730
    CrossrefPubMedGoogle Scholar
  • 5 Teede HJ, Tay CT, Laven J. et al; International PCOS Network. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Hum Reprod 2023; 38 (09) 1655-1679
    CrossrefPubMedGoogle Scholar
  • 6 Dietz de Loos A, Hund M, Buck K, Meun C, Sillman J, Laven JSE. Antimüllerian hormone to determine polycystic ovarian morphology. Fertil Steril 2021; 116 (04) 1149-1157
    CrossrefPubMedGoogle Scholar
  • 7 Jarrett BY, Vanden Brink H, Oldfield AL, Lujan ME. Ultrasound characterization of disordered antral follicle development in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2020; 105 (11) e3847-e3861
    CrossrefPubMedGoogle Scholar
  • 8 Dewailly D, Barbotin AL, Dumont A, Catteau-Jonard S, Robin G. Role of anti-Müllerian hormone in the pathogenesis of polycystic ovary syndrome. Front Endocrinol (Lausanne) 2020; 11: 641
    CrossrefPubMedGoogle Scholar
  • 9 Pellatt L, Hanna L, Brincat M. et al. Granulosa cell production of anti-Müllerian hormone is increased in polycystic ovaries. J Clin Endocrinol Metab 2007; 92 (01) 240-245
    CrossrefPubMedGoogle Scholar
  • 10 Qureshi AI, Nussey SS, Bano G, Musonda P, Whitehead SA, Mason HD. Testosterone selectively increases primary follicles in ovarian cortex grafted onto embryonic chick membranes: relevance to polycystic ovaries. Reproduction 2008; 136 (02) 187-194
    CrossrefPubMedGoogle Scholar
  • 11 Xu J, Bishop CV, Lawson MS, Park BS, Xu F. Anti-Müllerian hormone promotes pre-antral follicle growth, but inhibits antral follicle maturation and dominant follicle selection in primates. Hum Reprod 2016; 31 (07) 1522-1530
    CrossrefPubMedGoogle Scholar
  • 12 Xu F, Lawson MS, Campbell SP. et al. Stage-dependent actions of antimüllerian hormone in regulating granulosa cell proliferation and follicular function in the primate ovary. F S Sci 2020; 1 (02) 161-171
    PubMedGoogle Scholar
  • 13 Durlinger AL, Gruijters MJ, Kramer P. et al. Anti-Müllerian hormone attenuates the effects of FSH on follicle development in the mouse ovary. Endocrinology 2001; 142 (11) 4891-4899
    CrossrefPubMedGoogle Scholar
  • 14 Pellatt L, Rice S, Dilaver N. et al. Anti-Müllerian hormone reduces follicle sensitivity to follicle-stimulating hormone in human granulosa cells. Fertil Steril 2011; 96 (05) 1246-51.e1
    CrossrefPubMedGoogle Scholar
  • 15 Sacchi S, D'Ippolito G, Sena P. et al. The anti-Müllerian hormone (AMH) acts as a gatekeeper of ovarian steroidogenesis inhibiting the granulosa cell response to both FSH and LH. J Assist Reprod Genet 2016; 33 (01) 95-100
    CrossrefPubMedGoogle Scholar
  • 16 Catteau-Jonard S, Jamin SP, Leclerc A, Gonzalès J, Dewailly D, di Clemente N. Anti-Mullerian hormone, its receptor, FSH receptor, and androgen receptor genes are overexpressed by granulosa cells from stimulated follicles in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2008; 93 (11) 4456-4461
    CrossrefPubMedGoogle Scholar
  • 17 Das M, Gillott DJ, Saridogan E, Djahanbakhch O. Anti-Mullerian hormone is increased in follicular fluid from unstimulated ovaries in women with polycystic ovary syndrome. Hum Reprod 2008; 23 (09) 2122-2126
    CrossrefPubMedGoogle Scholar
  • 18 Bhide P, Dilgil M, Gudi A, Shah A, Akwaa C, Homburg R. Each small antral follicle in ovaries of women with polycystic ovary syndrome produces more antimüllerian hormone than its counterpart in a normal ovary: an observational cross-sectional study. Fertil Steril 2015; 103 (02) 537-541
    CrossrefPubMedGoogle Scholar
  • 19 Bhide P, Kulkarni A, Dilgil M. et al. Phenotypic variation in anti-Mullerian hormone (AMH) production per follicle in women with polycystic ovary syndrome (PCOS) and isolated polycystic ovarian morphology (PCOM): an observational cross-sectional study. Gynecol Endocrinol 2017; 33 (10) 801-806
    CrossrefPubMedGoogle Scholar
  • 20 Owens LA, Kristensen SG, Lerner A. et al. Gene expression in granulosa cells from small antral follicles from women with or without polycystic ovaries. J Clin Endocrinol Metab 2019; 104 (12) 6182-6192
    CrossrefPubMedGoogle Scholar
  • 21 Kristensen SG, Kumar A, Kalra B. et al. Quantitative differences in TGF-β family members measured in small antral follicle fluids from women with or without PCO. J Clin Endocrinol Metab 2019; 104 (12) 6371-6384
    CrossrefPubMedGoogle Scholar
  • 22 Dilaver N, Pellatt L, Jameson E. et al. The regulation and signalling of anti-Müllerian hormone in human granulosa cells: relevance to polycystic ovary syndrome. Hum Reprod 2019; 34 (12) 2467-2479
    PubMedGoogle Scholar
  • 23 Durlinger AL, Gruijters MJ, Kramer P. et al. Anti-Müllerian hormone inhibits initiation of primordial follicle growth in the mouse ovary. Endocrinology 2002; 143 (03) 1076-1084
    CrossrefPubMedGoogle Scholar
  • 24 Carlsson IB, Scott JE, Visser JA, Ritvos O, Themmen AP, Hovatta O. Anti-Müllerian hormone inhibits initiation of growth of human primordial ovarian follicles in vitro. Hum Reprod 2006; 21 (09) 2223-2227
    CrossrefPubMedGoogle Scholar
  • 25 Rice S, Ojha K, Whitehead S, Mason H. Stage-specific expression of androgen receptor, follicle-stimulating hormone receptor, and anti-Müllerian hormone type II receptor in single, isolated, human preantral follicles: relevance to polycystic ovaries. J Clin Endocrinol Metab 2007; 92 (03) 1034-1040
    CrossrefPubMedGoogle Scholar
  • 26 Willis DS, Watson H, Mason HD, Galea R, Brincat M, Franks S. Premature response to luteinizing hormone of granulosa cells from anovulatory women with polycystic ovary syndrome: relevance to mechanism of anovulation. J Clin Endocrinol Metab 1998; 83 (11) 3984-3991
    PubMedGoogle Scholar
  • 27 Foong SC, Abbott DH, Zschunke MA, Lesnick TG, Phy JL, Dumesic DA. Follicle luteinization in hyperandrogenic follicles of polycystic ovary syndrome patients undergoing gonadotropin therapy for in vitro fertilization. J Clin Endocrinol Metab 2006; 91 (06) 2327-2333
    CrossrefPubMedGoogle Scholar
  • 28 Tata B, Mimouni NEH, Barbotin AL. et al. Elevated prenatal anti-Müllerian hormone reprograms the fetus and induces polycystic ovary syndrome in adulthood. Nat Med 2018; 24 (06) 834-846
    CrossrefPubMedGoogle Scholar
  • 29 Mimouni NEH, Paiva I, Barbotin AL. et al. Polycystic ovary syndrome is transmitted via a transgenerational epigenetic process. Cell Metab 2021; 33 (03) 513-530.e8
    CrossrefPubMedGoogle Scholar
  • 30 Gorsic LK, Kosova G, Werstein B. et al. Pathogenic anti-Müllerian hormone variants in polycystic ovary syndrome. J Clin Endocrinol Metab 2017; 102 (08) 2862-2872
    CrossrefPubMedGoogle Scholar
  • 31 Gorsic LK, Dapas M, Legro RS, Hayes MG, Urbanek M. Functional genetic variation in the anti-Müllerian hormone pathway in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2019; 104 (07) 2855-2874
    CrossrefPubMedGoogle Scholar
  • 32 Stener-Victorin E, Padmanabhan V, Walters KA. et al. Animal models to understand the etiology and pathophysiology of polycystic ovary syndrome. Endocr Rev 2020; 41 (04) bnaa010
    CrossrefPubMedGoogle Scholar
  • 33 Stener-Victorin E. Update on animal models of polycystic ovary syndrome. Endocrinology 2022; 163 (12) bqac164
    CrossrefPubMedGoogle Scholar
  • 34 Schwanzel-Fukuda M, Pfaff DW. Origin of luteinizing hormone-releasing hormone neurons. Nature 1989; 338 (6211): 161-164
    CrossrefPubMedGoogle Scholar
  • 35 Wray S, Grant P, Gainer H. Evidence that cells expressing luteinizing hormone-releasing hormone mRNA in the mouse are derived from progenitor cells in the olfactory placode. Proc Natl Acad Sci U S A 1989; 86 (20) 8132-8136
    CrossrefPubMedGoogle Scholar
  • 36 Amato E, Taroc EZM, Forni PE. Illuminating the terminal nerve: uncovering the link between GnRH-1 and olfactory development. bioRxiv 2023; DOI: 10.1101/2023.08.31.555770.
    CrossrefPubMedGoogle Scholar
  • 37 Terasawa E. Mechanism of pulsatile GnRH release in primates: unresolved questions. Mol Cell Endocrinol 2019; 498: 110578
    CrossrefPubMedGoogle Scholar
  • 38 Campbell RE, Coolen LM, Hoffman GE, Hrabovszky E. Highlights of neuroanatomical discoveries of the mammalian gonadotropin-releasing hormone system. J Neuroendocrinol 2022; 34 (05) e13115
    CrossrefPubMedGoogle Scholar
  • 39 Malone SA, Papadakis GE, Messina A. et al. Defective AMH signaling disrupts GnRH neuron development and function and contributes to hypogonadotropic hypogonadism. eLife 2019; 8: e47198
    CrossrefPubMedGoogle Scholar
  • 40 Silva MSB, Giacobini P. New insights into anti-Müllerian hormone role in the hypothalamic-pituitary-gonadal axis and neuroendocrine development. Cell Mol Life Sci 2021; 78 (01) 1-16
    CrossrefPubMedGoogle Scholar
  • 41 Silva MSB, Decoster L, Delpouve G. et al. Overactivation of GnRH neurons is sufficient to trigger polycystic ovary syndrome-like traits in female mice. EBioMedicine 2023; 97: 104850
    CrossrefPubMedGoogle Scholar
  • 42 Simerly RB, Young BJ. Regulation of estrogen receptor messenger ribonucleic acid in rat hypothalamus by sex steroid hormones. Mol Endocrinol 1991; 5 (03) 424-432
    CrossrefPubMedGoogle Scholar
  • 43 McQuillan HJ, Clarkson J, Kauff A. et al. Definition of the estrogen negative feedback pathway controlling the GnRH pulse generator in female mice. Nat Commun 2022; 13 (01) 7433
    CrossrefPubMedGoogle Scholar
  • 44 Dubois SL, Acosta-Martínez M, DeJoseph MR. et al. Positive, but not negative feedback actions of estradiol in adult female mice require estrogen receptor α in kisspeptin neurons. Endocrinology 2015; 156 (03) 1111-1120
    CrossrefPubMedGoogle Scholar
  • 45 Foecking EM, McDevitt MA, Acosta-Martínez M, Horton TH, Levine JE. Neuroendocrine consequences of androgen excess in female rodents. Horm Behav 2008; 53 (05) 673-692
    CrossrefPubMedGoogle Scholar
  • 46 McCartney CR, Campbell RE, Marshall JC, Moenter SM. The role of gonadotropin-releasing hormone neurons in polycystic ovary syndrome. J Neuroendocrinol 2022; 34 (05) e13093
    CrossrefPubMedGoogle Scholar
  • 47 Sullivan SD, Moenter SM. Prenatal androgens alter GABAergic drive to gonadotropin-releasing hormone neurons: implications for a common fertility disorder. Proc Natl Acad Sci U S A 2004; 101 (18) 7129-7134
    CrossrefPubMedGoogle Scholar
  • 48 Dumesic DA, Winnett C, Lu G. et al. Randomized clinical trial: effect of low-dose flutamide on abdominal adipogenic function in normal-weight women with polycystic ovary syndrome. Fertil Steril 2023; 119 (01) 116-126
    CrossrefPubMedGoogle Scholar
  • 49 Hevener AL, Clegg DJ, Mauvais-Jarvis F. Impaired estrogen receptor action in the pathogenesis of the metabolic syndrome. Mol Cell Endocrinol 2015; 418 (Pt 3): 306-321
    CrossrefPubMedGoogle Scholar
  • 50 Gambineri A, Patton L, Vaccina A. et al. Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. J Clin Endocrinol Metab 2006; 91 (10) 3970-3980
    CrossrefPubMedGoogle Scholar
  • 51 Gambineri A, Pelusi C, Genghini S. et al. Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2004; 60 (02) 241-249
    CrossrefPubMedGoogle Scholar
  • 52 Behringer RR, Cate RL, Froelick GJ, Palmiter RD, Brinster RL. Abnormal sexual development in transgenic mice chronically expressing Müllerian inhibiting substance. Nature 1990; 345 (6271): 167-170
    CrossrefPubMedGoogle Scholar
  • 53 Ho EV, Shi C, Cassin J. et al. Reproductive deficits induced by prenatal antimüllerian hormone exposure require androgen receptor in kisspeptin cells. Endocrinology 2021; 162 (12) bqab197
    CrossrefPubMedGoogle Scholar
  • 54 Risal S, Pei Y, Lu H. et al. Prenatal androgen exposure and transgenerational susceptibility to polycystic ovary syndrome. Nat Med 2019; 25 (12) 1894-1904
    CrossrefPubMedGoogle Scholar
  • 55 Piltonen TT, Giacobini P, Edvinsson Å. et al. Circulating antimüllerian hormone and steroid hormone levels remain high in pregnant women with polycystic ovary syndrome at term. Fertil Steril 2019; 111 (03) 588-596.e1
    CrossrefPubMedGoogle Scholar
  • 56 Peigné M, Simon V, Pigny P. et al. Changes in circulating forms of anti-Müllerian hormone and androgens in women with and without PCOS: a systematic longitudinal study throughout pregnancy. Hum Reprod 2023; 38 (05) 938-950
    CrossrefPubMedGoogle Scholar
  • 57 Valdimarsdottir R, Valgeirsdottir H, Wikström AK. et al. Pregnancy and neonatal complications in women with polycystic ovary syndrome in relation to second-trimester anti-Müllerian hormone levels. Reprod Biomed Online 2019; 39 (01) 141-148
    CrossrefPubMedGoogle Scholar
  • 58 Köninger A, Kampmeier A, Schmidt B. et al. Trends in anti-Müllerian hormone concentrations across different stages of pregnancy in women with polycystic ovary syndrome. Reprod Biomed Online 2018; 37 (03) 367-374
    CrossrefPubMedGoogle Scholar
  • 59 Kollmann M, Obermayer-Pietsch B, Lerchbaum E. et al. Androgen and anti-Mullerian hormone concentrations at term in newborns and their mothers with and without polycystic ovary syndrome. J Clin Med 2019; 8 (11) 1817
    CrossrefPubMedGoogle Scholar
  • 60 Maliqueo M, Lara HE, Sánchez F, Echiburú B, Crisosto N, Sir-Petermann T. Placental steroidogenesis in pregnant women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2013; 166 (02) 151-155
    CrossrefPubMedGoogle Scholar
  • 61 Vanky E, Carlsen SM. Androgens and antimüllerian hormone in mothers with polycystic ovary syndrome and their newborns. Fertil Steril 2012; 97 (02) 509-515
    CrossrefPubMedGoogle Scholar
  • 62 Yang M, Zhang F, Wu K. et al. Müllerian duct anomalies and anti-Müllerian hormone levels in women with polycystic ovary syndrome. Cureus 2023; 15 (08) e43848
    PubMedGoogle Scholar
  • 63 Zhou S, Lu D, Wen S, Sheng Y, Kang D, Xu L. Elevated anti-Müllerian hormone levels in newborns of women with polycystic ovary syndrome: a systematic review and meta-analysis based on observational studies. Reprod Sci 2022; 29 (01) 301-311
    CrossrefPubMedGoogle Scholar
  • 64 Detti L, Christiansen ME, Francillon L. et al. Serum anti-Müllerian hormone (AMH) in mothers with polycystic ovary syndrome (PCOS) and their term fetuses. Syst Biol Reprod Med 2019; 65 (02) 147-154
    CrossrefPubMedGoogle Scholar
  • 65 Baydemir ŞK, Sukur YE, Ersan N, Dogan O, Atabekoglu CS. Cord blood anti-Müllerian hormone levels are higher in female newborns from women with polycystic ovary syndrome (PCOS) when compared to non-PCOS controls, irrespective of body mass index; a prospective case-control study. JBRA Assist Reprod 2023; 27 (03) 422-427
    PubMedGoogle Scholar
  • 66 Tadaion Far F, Jahanian Sadatmahalleh S, Ziaei S, Kazemnejad A. Comparison of the umbilical cord blood's anti-Mullerian hormone level in the newborns of mothers with polycystic ovary syndrome (PCOS) and healthy mothers. J Ovarian Res 2019; 12 (01) 111
    CrossrefPubMedGoogle Scholar
  • 67 Sir-Petermann T, Codner E, Pérez V. et al. Metabolic and reproductive features before and during puberty in daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2009; 94 (06) 1923-1930
    CrossrefPubMedGoogle Scholar
  • 68 Torchen LC, Legro RS, Dunaif A. Distinctive reproductive phenotypes in peripubertal girls at risk for polycystic ovary syndrome. J Clin Endocrinol Metab 2019; 104 (08) 3355-3361
    CrossrefPubMedGoogle Scholar
  • 69 Barrett ES, Hoeger KM, Sathyanarayana S. et al. Anogenital distance in newborn daughters of women with polycystic ovary syndrome indicates fetal testosterone exposure. J Dev Orig Health Dis 2018; 9 (03) 307-314
    CrossrefPubMedGoogle Scholar
  • 70 Zamani P, Hemati Z, Kelishadi R, Kolahdozan S, Dianatinasab M, Keikha M. Association between anogenital distance as a noninvasive index in the diagnosis and prognosis of reproductive disorder: a systematic review. Int J Reprod Biomed (Yazd) 2023; 21 (08) 599-618
    PubMedGoogle Scholar
  • 71 Crisosto N, Ladrón de Guevara A, Echiburú B. et al. Higher luteinizing hormone levels associated with antimüllerian hormone in postmenarchal daughters of women with polycystic ovary syndrome. Fertil Steril 2019; 111 (02) 381-388
    CrossrefPubMedGoogle Scholar
  • 72 Legro RS, Driscoll D, Strauss III JF, Fox J, Dunaif A. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci U S A 1998; 95 (25) 14956-14960
    CrossrefPubMedGoogle Scholar
  • 73 Abbott DH, Rayome BH, Dumesic DA. et al. Clustering of PCOS-like traits in naturally hyperandrogenic female rhesus monkeys. Hum Reprod 2017; 32 (04) 923-936
    CrossrefPubMedGoogle Scholar
  • 74 Bourgneuf C, Bailbé D, Lamazière A. et al. The Goto-Kakizaki rat is a spontaneous prototypical rodent model of polycystic ovary syndrome. Nat Commun 2021; 12 (01) 1064
    CrossrefPubMedGoogle Scholar
  • 75 Abedal-Majed MA, Abuajamieh M, Al-Qaisi M. et al. Sheep with ovarian androgen excess have fibrosis and follicular arrest with increased mRNA abundance for steroidogenic enzymes and gonadotropin receptors. J Anim Sci 2023; 101: skad082
    CrossrefPubMedGoogle Scholar
  • 76 Summers AF, Pohlmeier WE, Sargent KM. et al. Altered theca and cumulus oocyte complex gene expression, follicular arrest and reduced fertility in cows with dominant follicle follicular fluid androgen excess. PLoS One 2014; 9 (10) e110683
    CrossrefPubMedGoogle Scholar
  • 77 Abedal-Majed MA, Springman SA, Jafar HD. et al. Naturally occurring androgen excess cows are present in dairy and beef herds and have similar characteristics to women with PCOS. J Anim Sci 2022; 100 (06) skac151
    CrossrefPubMedGoogle Scholar
  • 78 Dumesic DA, Patankar MS, Barnett DK, Lesnick TG, Hutcherson BA, Abbott DH. Early prenatal androgenization results in diminished ovarian reserve in adult female rhesus monkeys. Hum Reprod 2009; 24 (12) 3188-3195
    CrossrefPubMedGoogle Scholar
  • 79 Dapas M, Dunaif A. Deconstructing a syndrome: genomic insights into PCOS causal mechanisms and classification. Endocr Rev 2022; 43 (06) 927-965
    CrossrefPubMedGoogle Scholar
  • 80 Meng L, McLuskey A, Dunaif A, Visser JA. Functional analysis of rare anti-Müllerian hormone protein-altering variants identified in women with PCOS. Mol Hum Reprod 2023; 29 (05) gaad011
    CrossrefPubMedGoogle Scholar
  • 81 Georgopoulos NA, Karagiannidou E, Koika V. et al. Increased frequency of the anti-Mullerian-inhibiting hormone receptor 2 (AMHR2) 482 A>G polymorphism in women with polycystic ovary syndrome: relationship to luteinizing hormone levels. J Clin Endocrinol Metab 2013; 98 (11) E1866-E1870
    CrossrefPubMedGoogle Scholar
  • 82 Moolhuijsen LME, Louwers YV, McLuskey A. et al. Association between an AMH promoter polymorphism and serum AMH levels in PCOS patients. Hum Reprod 2022; 37 (07) 1544-1556
    CrossrefPubMedGoogle Scholar
  • 83 Campbell BK, Clinton M, Webb R. The role of anti-Müllerian hormone (AMH) during follicle development in a monovulatory species (sheep). Endocrinology 2012; 153 (09) 4533-4543
    CrossrefPubMedGoogle Scholar
  • 84 Chen M, Guo X, Zhong Y. et al. AMH inhibits androgen production in human theca cells. J Steroid Biochem Mol Biol 2023; 226: 106216
    CrossrefPubMedGoogle Scholar
  • 85 McAllister JM, Modi B, Miller BA. et al. Overexpression of a DENND1A isoform produces a polycystic ovary syndrome theca phenotype. Proc Natl Acad Sci U S A 2014; 111 (15) E1519-E1527
    CrossrefPubMedGoogle Scholar
  • 86 McAllister JM, Legro RS, Modi BP, Strauss III JF. Functional genomics of PCOS: from GWAS to molecular mechanisms. Trends Endocrinol Metab 2015; 26 (03) 118-124
    CrossrefPubMedGoogle Scholar
  • 87 Waterbury JS, Teves ME, Gaynor A. et al. The PCOS GWAS candidate gene ZNF217 influences theca cell expression of DENND1A.V2, CYP17A1, and androgen production. J Endocr Soc 2022; 6 (07) bvac078
    CrossrefPubMedGoogle Scholar